» Articles » PMID: 16278009

Polymorphisms in the Promoter Regions of the Matrix Metalloproteinases-1, -3, -7, and -9 and the Risk of Epithelial Ovarian Cancer in China

Overview
Journal Gynecol Oncol
Date 2005 Nov 10
PMID 16278009
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To investigate the association of single nucleotide polymorphisms (SNP) in the promoter region of the matrix metalloproteinases-1 -1607bp1G/2G, matrix metalloproteinases-3 -1171bp5A/6A, matrix metalloproteinases-7 A-181G and matrix metalloproteinases-9 C-1562T with susceptibility to ovarian cancer in a population of North China.

Experimental Design: We analyzed four different functional promoter polymorphisms in the respective genes by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) in a sample of patients with epithelium ovarian cancer and control women, all from North China.

Results: No significant difference was detected between the patient and control groups in genotype and allelotype distribution of MMP-1, MMP-3, MMP-9 of the polymorphisms studied. However, the genotype and allelotype of the MMP-7 distribution in ovarian cancer patients were significantly different from that in healthy controls. The frequency of the -181G allele of MMP-7 in patients was significantly higher than that in healthy controls women (8.2% vs. 2.8%, P = 0.002). Compared to the A/A genotype, the genotypes with the -181G allele (A/G + G/G) significantly increased susceptibility to ovarian cancer, with adjusted odds ratio [OR] = 3.53 95% confidence interval [CI] [1.58 to 7.89].

Conclusions: The study suggested that a possible association between the MMP-7 A/G polymorphism with susceptibility to epithelium ovarian cancer, but there is no support for an association of the selected MMP-1 1G/2G, MMP-3 5A/6A, and MMP-9 C/T polymorphisms with the risk for ovarian cancer.

Citing Articles

MMP-3 gene regulates the carcinogenesis and metabolic process of ovarian cancer, evidence from a Chinese population: Observational study and meta-analysis.

Wang L, Yao Y, Si D Medicine (Baltimore). 2023; 102(50):e36471.

PMID: 38115289 PMC: 10727570. DOI: 10.1097/MD.0000000000036471.


Approaches Toward Targeting Matrix Metalloproteases for Prognosis and Therapies in Gynecological Cancer: MicroRNAs as a Molecular Driver.

Pandit A, Begum Y, Saha P, Srivastava A, Swarnakar S Front Oncol. 2022; 11:720622.

PMID: 35145899 PMC: 8821656. DOI: 10.3389/fonc.2021.720622.


Association of Matrix Metalloproteinase-1 Genotypes With Bladder Cancer Risk.

Liao C, Tsai C, Chang W, Wang Z, Gong C, Wu H In Vivo. 2021; 35(5):2535-2540.

PMID: 34410940 PMC: 8408719. DOI: 10.21873/invivo.12535.


A Matrix Metalloproteinase-1 Polymorphism, (1G>2G), Is Associated with Increased Cancer Risk: A Meta-Analysis Including 21,327 Patients.

Zhou Z, Ma X, Wang F, Sun L, Zhang G Dis Markers. 2019; 2018:7565834.

PMID: 30627228 PMC: 6305015. DOI: 10.1155/2018/7565834.


The Association of Promoter Polymorphisms with Breast Cancer.

Hsiao C, Liu L, Shih T, Lai Y, Hsu S, Wang H In Vivo. 2018; 32(3):487-491.

PMID: 29695550 PMC: 6000806. DOI: 10.21873/invivo.11265.